Q32 Bio Inc. (LON:0T6G)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 159.68M +834.3% |
| Revenue (ttm) | 40.70M |
| Net Income | 25.18M |
| EPS | 1.97 |
| Shares Out | n/a |
| PE Ratio | 6.34 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,394 |
| Open | 12.25 |
| Previous Close | 12.36 |
| Day's Range | 12.25 - 13.60 |
| 52-Week Range | 1.32 - 14.77 |
| Beta | -0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Q32 Bio
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatm... [Read more]
News
Q32 Bio Transcript: AGM 2026
The meeting covered director elections, audit firm ratification, and executive compensation, with all proposals approved by stockholders. Voting results will be included in official minutes and SEC filings.
3 Penny Stocks to Watch Now, 5/28/26
Astrotech Corporation ($ASTC), Momentus ($MNTS), and Q32 Bio ($QTTB) are the three penny stocks to watch on May 28, according to TipRanks’ Penny Stock Screener tool. Penny stocks are shares…
Q32 Bio Inc trading halted, volatility trading pause
09:32 EDT Q32 Bio (QTTB) Inc trading halted, volatility trading pause
Q32 Bio announces $55M private placement
Q32 Bio (QTTB) announced that it has entered into a securities purchase agreement with certain new and existing institutional and accredited investors for the private placement of common stock and…
Q32 Bio Announces $55 Million Private Placement Financing
WALTHAM, Mass., May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata...
Q32 Bio initiated with an Outperform at Mizuho
Mizuho analyst Joseph Catanzaro initiated coverage of Q32 Bio (QTTB) with an Outperform rating and $14 price target The company’s lead program bempikibart offers a “highly competitive” non-JAK inhibit...
Q32 Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Q32 Bio (QTTB) with an Overweight rating.
Q32 Bio Earnings release: Q1 2026
Q32 Bio released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Q32 Bio Quarterly report: Q1 2026
Q32 Bio has published its Q1 2026 quarterly earnings report on May 5, 2026.
Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
-- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 -- -- First patient dosed in SIGNAL-AA Part B open-label extension (OLE) -- -- Comple...
Q32 Bio Slides: Company presentation
Q32 Bio has posted slides in relation to its latest quarterly earnings report, which was published on May 4, 2026.
Q32 Bio Proxy statement: Proxy filing
Q32 Bio filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Q32 Bio Proxy statement: Proxy filing
Q32 Bio filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Q32 Bio Transcript: 25th Annual Needham Virtual Healthcare Conference
Bempikibart, a bifunctional antibody for alopecia areata, is in phase II with mid-year data expected. The drug targets key immune pathways and aims to address significant unmet needs with a differentiated safety and administration profile. Cash runway extends through Q4 2027.
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ot...
Q32 Bio Annual report: Q4 2025
Q32 Bio has published its Q4 2025 annual report on March 10, 2026.
Q32 Bio Earnings release: Q4 2025
Q32 Bio released its Q4 2025 earnings on March 10, 2026, summarizing the period's financial results.
Q32 Bio Slides: Company presentation
Q32 Bio has posted slides in relation to its latest quarterly earnings report, which was published on March 10, 2026.
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Complete...
Q32 Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Bempikibart is advancing in alopecia areata with promising proof-of-concept and a robust phase IIa program, aiming to address unmet needs with a safer, durable biologic. Top-line 36-week data are expected midyear, with a focus on expanding into other T-cell driven diseases.
Q32 Bio initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Q32 Bio (QTTB) with a Buy rating and $13 price target The firm says the company’s bempikibart targets an opportunity in alopecia areata where current…
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ot...
Q32 Bio announces $10.5M registered direct offering
Q32 Bio (QTTB) announced a $10.5M registered direct offering. This transaction was led by a new institutional investor with participation by an existing dedicated public institutional investor. Q32 Bi...
Q32 Bio Announces $10.5 Million Registered Direct Offering
WALTHAM, Mass., Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ot...